Angiogenesis, the formation of new capillaries from preexisting vessels, is essential for tumor progression. Ursolic acid inhibited the tumor-associated capillary formation in C57BL/6 mice induced by highly metastatic B16F-10 melanoma cells. The levels of serum vascular endothelial growth factor (VEGF), NO, and proinflammatory cytokines were significantly reduced in ursolic acid-treated animals compared with those in control animals. The diminished expressions of VEGF and iNOS genes in B16F-10 melanoma cells treated with nontoxic concentrations of ursolic acid support these observations; the serum TIMP-1 (tissue inhibitor of metalloproteinase-1) and IL-2 (interleukin-2) levels were significantly elevated after the ursolic acid treatment. Nontoxic concentrations of ursolic acid toward human umbilical vein endothelial cells (HUVEC) were determined by MTT (methylthiazol tetrazolium) assay, and these nontoxic concentrations were selected for the in vitro studies. Nontoxic concentrations of ursolic acid inhibited vessel growth from the rat aortic ring. 3 H-thymidine proliferation assay clearly showed the inhibitory effect of ursolic acid on the proliferation of HUVECs in vitro. Ursolic acid significantly inhibited endothelial cell migration and invasion. The role of metalloproteinases has been shown to be important in angiogenesis; therefore, gelatin zymography was performed to determine whether ursolic acid affected protease activity. Gelatin zymographic analysis showed the inhibitory effect of ursolic acid on the protein expression of matrix metalloproteinases MMP-2 and MMP-9. The above observation shows the antiangiogenic activity of ursolic acid.
Introduction
Angiogenesis is an essential process during development: growth of a vascular system is one of the earliest events in organogenesis. Nonetheless, it also occurs in adulthood, during wound healing, and restoration of blood flow to injured tissues. Angiogenesis is regulated by a very sensitive interplay of growth factors and inhibitors, and their imbalance can lead to disease. In cancer, excessive angiogenesis feeds diseased tissue and destroys normal tissue. Angiogenesis does not initiate malignancy but promotes tumor progression and metastasis. Unlike tumor cells, endothelial cells are genomically stable and were therefore originally considered to be ideal therapeutic targets that would not become resistant to antiangiogenic therapy.
The progression of tumors is largely dependent on their vascularization. 1, 2 The term angiogenic switch describes the expression of specific genes that alter the balance between proangiogenic and antiangiogenic molecules produced by tumor cells themselves and by cells of the host microenvironment. [3] [4] [5] Vascular relaxation, for example, mediated by nitric oxide (NO) is a prerequisite for endothelial cells to enter the angiogenic cascade. NO is a multifunctional species that is implicated in a wide variety of physiological and pathological processes. 6, 7 A family of 3 isoenzymes called nitric oxide synthases produce NO from l-arginine 7,8 ; two (cNOS) are constitutively expressed, and the third one (iNOS) is inducible by immunological stimuli.
It is suggested that the vascular endothelial growth factor (VEGF) is a major player in angiogenesis initiation based on its ability to induce vasodilation via endothelial NO production and its endothelial cell permeability increasing effect. 9 The pleiotropic effects of VEGF in vitro on endothelial cell growth, proliferation, and migration, among others, have now been extensively documented by many groups. VEGF is abundantly produced by hypoxic tumor cells, macrophages, and other cells of the immune system. 10 Cytokines are a large family of soluble proteins that serve as mediators of immune responses participating in the communication and regulation of inflammatory responses. 11 Several inflammatory cytokines have been linked with 1 Amala Cancer Research Centre, Thrissur, Kerala, India tumorigenesis, which suggests that inflammation is associated with cancer development. 12 Studies have indicated that tumor cells exhibit an elevation in the constitutive production of proinflammatory cytokines such as tumor necrosis factor-a (TNF-a), interleukin-1b (IL-1b), and IL-6. The proinflammatory cytokine TNF-a is a mediator of NO synthesis. 13 Activated macrophages and monocytes produce TNF-a, which in turn induces various immune responses such as the release of soluble mediators like PGE2, leukotrienes, platelet-activating factor, NO, and reactive oxygen intermediates. 14 These are found to stimulate angiogenesis 15 and the formation of endothelial cell tubes. 16 After proper activation of the endothelial cells, endothelial penetration into new areas of the body is achieved by degradation of the basement membrane by matrix metalloproteinases (MMPs). MMP activity, and hence angiogenesis, is counteracted by the family of tissue inhibitors of metalloproteinase (TIMPs). 17, 18 Terpenoids are a class of compounds widely distributed in plants. 19 They occur widely in fruits and vegetables consumed by humans. Many of them have been shown to inhibit chemically induced tumors. 20 Although terpenoids are widely used for medicinal purposes in many Asian countries, their biogenesis and pleiotropic actions have not had an effect on the practice of Western medicine. 21 Ursolic acid is a pentacyclic triterpenoid compound ( Figure 1 ) isolated from many types of medicinal plants. It is the major component of extracts of the Chinese herb, Souyang. It has been reported to possess a wide range of pharmacological properties and is one of the most promising chemopreventive agents for cancer. 22 Ursolic acid has been reported to induce apoptosis through the mitochondrial intrinsic pathway through caspase 3 activation in M4Beu melanoma cells and to inhibit proliferation through cell cycle arrest in B16 melanoma cells. 23, 24 We have already found that nontoxic concentrations of ursolic acid can induce apoptosis in B16F-10 melanoma cells by inhibiting NF-kB. 25 We also reported the immunomodulatory effect of ursolic acid. 26 Previous studies showed that ursolic acid has some antiangiogenic properties, [27] [28] [29] and in the present study, we attempt to demonstrate the effect of ursolic acid on inhibiting tumorinduced angiogenesis using in vivo and in vitro models.
Materials and Methods Animals
C57BL/6 mice (male, 4-6 weeks old, 20-25 g body weight) were purchased from the National Institute of Nutrition, Hyderabad, India. The animals were fed with mouse chow (Sai Durga Feeds, Bangalore, India) and water ad libitum. All the animal experiments were conducted according to the rules and regulations of the Animals Ethics Committee, Government of India.
Cell Lines
Human umbilical vein endothelial cells (HUVECs) were isolated from the human umbilical cord vein by collagenase treatment as described by Jaffe et al. 30 The cells were grown in medium 199, supplemented with 20% fetal calf serum (FCS), 100 units/mL penicillin, 100 mg/mL streptomycin, and 2 ng/mL VEGF and fibroblast growth factor at 37°C in 5% CO 2 atmosphere. The B16F-10 melanoma cell line was obtained from the National Centre for Cell Sciences, Pune. Cells were grown in Dulbecco's Modified Eagle Medium (DMEM) (Hi Media, Mumbai, India) supplemented with 20% FCS and antibiotics.
ELISA Kit
Highly specific quantitative sandwich ELISA kit for mouse IL-2, TNF-a, IL-1b, and IL-6 were purchased from Pierce Biotechnology (Rockford, IL), and ELISA kits for VEGF and TIMP-1 were purchased from R & D System (St Paul, MN). in light paraffin oil and administered intraperitoneally. For in vitro studies, ursolic acid was dissolved in 1% dimethyl sulfoxide and medium 199 with FCS.
Determination of the Effect of Ursolic Acid on Tumor-Specific Capillary Formation
Angiogenesis was induced in 3 groups of C57BL/6 mice (n = 8/group) by injecting B16F-10 melanoma cells (10 6 cells/ animal) intradermally on the shaven ventral skin of each mouse. Group I animals were treated with the vehicle alone and kept as controls. Group II animals were treated with 5 doses of ursolic acid (50 mmol/kg body weight) for 5 consecutive days starting simultaneously with the tumor challenge. The animals were killed humanely on the ninth day after the induction of angiogenesis. The skin from the ventral side was dissected out and washed with phosphate buffered saline (PBS), and the number of tumor-directed capillaries was counted using a dissection microscope.
Determination of the Effect of Ursolic Acid on Serum VEGF, TIMP-1, IL-2 and Proinflammatory Cytokine Levels During Angiogenesis
Blood was collected from the above animals at 2 time intervals-at the 24th hour and on the ninth day after the induction of angiogenesis-and the serum was used for estimating the levels of VEGF, TIMP-1, IL-2, and proinflammatory cytokines like TNF-a, IL-1b, and IL-6 using ELISA kits as per the manufacturer's protocol.
Determination of the Effect of Ursolic Acid on Serum Nitrite Levels During Angiogenesis
Blood was collected from all animals (grouped above) at 2 time intervals-the 24th hour and the ninth day after the induction of angiogenesis-and the serum was used for the estimation of nitrite levels. Nitrite level in the serum was determined by Griess' reaction. 31 Briefly, a 100-mL sample was incubated with an equal amount of Griess' reagent (1 part of 0.1% N(1-naphthyl)-diamine dihydrochloride in distilled water and 1 part 1% sulfanilamide in 5% concentrated phosphoric acid) and incubated for 10 minutes at room temperature. Absorbance was estimated at 540 nm. The amount of nitrite was calculated from the NaNO 2 standard curve.
Determination of Cytotoxic Activity of Ursolic Acid Toward HUVECs in Culture by MTT Assay
HUVECs were seeded (5000 cells/well) in a 96-well flatbottomed titer plate and incubated for 24 hours at 37°C in 5% CO 2 atmosphere. Different concentrations of ursolic acid (10-100 mM) were added and incubated further for 48 hours. Before completion of 4 hours of incubation, 20 mL MTT (5 mg/mL) was added. The percentage of dead cells was determined using an ELISA plate reader set to record absorbance at 570 nm.
Determination of the Effect of Ursolic Acid on the Microvessel Outgrowth From the Rat Aortic Ring (Rat Aortic Ring Assay)
The rat aortic ring assay was used as the in vitro angiogenesis study model. 32 The dorsal aorta from a freshly killed Sprague-Dawley rat was taken out in a sterile manner and rinsed in ice-cold PBS. It was then cut into ~1-mm long pieces using surgical blades. Each ring was placed in a collagen precoated 96-well plate. The rings were incubated for 24 hours at 37°C in complete medium and then replaced with conditioned medium from B16F-10 melanoma cells and incubated with or without different nontoxic concentrations of ursolic acid (10, 25, and 50 mM). On day 6, the rings were analyzed by phase-contrast microscopy for microvessel outgrowth and photographed.
Determination of the Effect of Ursolic Acid on Endothelial Cell Proliferation ( 3 H-thymidine Incorporation Assay)
HUVECs (5000 cells/well) were seeded in a 96-well culture plate and incubated at 37°C in 5% CO 2 atmosphere. After 24 hours, various nontoxic concentrations of ursolic acid (10, 25, and 50 mM) were added along with 2 ng/mL VEGF and further incubated for 48 hours. 3 H-thymidine was added to each well (1 mCi/well), and incubation was continued for an additional 18 hours. After completing incubation, the plates were centrifuged, and the culture supernatant was removed; the cells were washed 3 times with PBS and then treated with ice-cold Perchloric acid (PCA) for 15 minutes. The resulting precipitate was dissolved in 0.5 N NaOH and was added to the scintillation fluid, and the radioactivity was counted using a Rackbeta liquid scintillation counter.
Determination of the Effect of Ursolic Acid on B16F-10 Melanoma Cell Proliferation ( 3 H-thymidine Incorporation Assay)
B16F-10 melanoma cells were seeded in a 96-well culture plate and incubated at 37°C in 5% CO 2 atmosphere. After 24 hours, various nontoxic concentrations of ursolic acid (10, 25, and 50 mM) were added and further incubated for 48 hours. After the incubation, the 3 H-thymidine incorporation assay was performed as discussed above.
Determination of the Effect of Ursolic Acid on Endothelial Cell Migration/Motility
HUVECs were seeded into wells of collagen-coated 96-well plates at a density of 2 × 10 5 cells/well and incubated for 24 hours at 37°C in 5% CO 2 atmosphere. A clear area was scraped in the monolayer with a narrow tip, by applying suction, and washed with serum-free medium. Different concentrations of ursolic acid (10, 25, and 50 mM) were added along with 2 ng/mL of VEGF and further incubated for 24 hours. After incubation, the cells were fixed in formalin, stained with crystal violet, and photographed (10×).
Determination of the Effect of Ursolic Acid on Endothelial Cell Invasion
The invasion assay was carried out in modified Boyden chambers as described by Albini. 33 The lower compartment of the chamber was filled with serum-free condition medium (DMEM) of B16F-10 melanoma cells, and a polycarbonate filter membrane coated with 25 mg of type I collagen was placed above this. HUVECs (10 5 cells/150 mL medium 199) were then seeded on to the upper chamber in the presence and absence of ursolic acid (10, 25, and 50 mM) and incubated at 37°C in 5% CO 2 atmosphere for 10 hours. After incubation, the filters were removed, fixed with methanol, and stained with crystal violet. Cells migrating to the lower surface of the polycarbonate filters were counted under a microscope. The results were expressed as percentage inhibition of invasion.
Determination of the Effect of Ursolic Acid on MMPs by Gelatin Zymography
SDS-PAGE was performed with 0.1% gelatin incorporated in the separating gel. 34 HUVECs of subconfluent cultures were treated with ursolic acid (10, 25, and 50 mM) for 24 hours at 37°C in 5% CO 2 atmosphere. The cells were then washed with PBS and incubated further for 24 hours in serum-free medium at 37°C in 5% CO 2 atmosphere. After 24 hours, the medium was collected and subjected to zymography analysis. Then, 50 mL of medium (equivalent to 100 mg protein) was activated with 5 mL trypsin solution (75 mg/mL) in 0.1 M Tris-HCl, 10 mM CaCl 2 buffer (pH 8.0) and incubated for 1 hour at room temperature. Samples were mixed with an equal volume of 2X sample buffer and loaded on to 11% polyacrylamide gels containing 0.1% gelatin. Electrophoresis was carried out at 4°C, with a constant current of 2 mA per tube until the tracking dye reached the periphery. The gels were then washed with 2% Triton X-100 in 0.1 M Tris-HCl, 10 mM CaCl 2 at 37°C for 18 hours followed by staining with GelCode Blue Stain Reagent for 2 hours. Gels were washed to visualize the clear area against the dark background.
Determination of the Effect of Ursolic Acid on the Expression of VEGF in B16F-10 Melanoma Cells
Logarithmically growing B16F-10 melanoma cells (5 × 10 4 ) were incubated for 4 hours in the presence and absence of nontoxic concentrations of ursolic acid (50 mM). 25 cDNA was synthesized using cell to cDNA kit (Ambion Inc). Cells were washed with PBS and heated in cell lysis buffer (provided in the kit) to release the RNA into the solution. This was followed by a heating step to inactivate endogenous RNases. The genomic DNA was further degraded by treating with DNase followed by inactivation of DNase by heating at 70°C. Reverse transcription was performed at 42°C for 50 minutes using Moloney murine leukemia virus RT (supplied along with the kit). Gene expression studies were done using specific mouse primers of VEGF ( Table 1 ). The following polymerase chain reaction (PCR) reaction profile was followed in the minicycler: 1 minute at 94°C, 1 minute at 55°C, and 1 minute at 72°C for 39 cycles followed by a 10-minute extension at 72°C. Amplified PCR products were subjected to electrophoresis on a 1.8% agarose gel and stained with ethidium bromide and photographed under UV light.
Determination of the Effect of Ursolic Acid on the Expression of iNOS and GAPDH
cDNA from the above experiment was amplified with the primers of the iNOS gene (iNOS) and the housekeeping gene, GAPDH, standard using PCR. The standard PCR products were generated by using positive control cDNA provided in the kit. The cycling conditions were as follows: 1 minute at 94.8°C, 1 minute at 58.8°C, and 1 minute at 72.8°C for 40 cycles, followed by a 10-minute extension at 72.8°C. Amplified PCR products were electrophoresed on a 1.8% agarose gel and stained with ethidium bromide and photographed under UV light. 
Statistical Analysis
Results were expressed as mean ± standard deviation. The statistical analysis was done by using 1-way ANOVA followed by Dunnett's test.
Results

Effect of Ursolic Acid on Tumor-Specific Capillary Formation
The number of tumor-directed capillaries was significantly (P < .001) reduced in the ursolic acid-treated animals (42.03%) compared with the control animals ( Figure 2 , Table 1 ). The group that received ursolic acid had an average of 12.67 ± 1.2 capillaries ( Figure 2B ), whereas the control group had an average of 30.14 ± 1.35 (Figure 2A ) capillaries.
Effect of Ursolic Acid on Serum VEGF Level During Angiogenesis
The level of serum VEGF showed a sudden increase in tumor-bearing control animals to 70.798 ± 1.1 pg/mL after 24 hours and 131.7 ± 18.86 pg/mL on the ninth day after tumor induction, compared with normal levels (16 ± 8.0 pg/mL). Ursolic acid-treated animals showed significant reduction in VEGF levels, which was only 42.53 ± 0.53 pg/mL and 61.63 ± 1.2 pg/mL after 24 hours and on the ninth day, respectively ( Table 2) .
Effect of Ursolic Acid on Serum NO Levels During Angiogenesis
The serum nitrite level of control animals at 24 hours after angiogenesis induction was slightly increased to 25.5 ± 0.27 mmol and further elevated drastically to 39.4 ± 0.797 mmol on the ninth day as the neovascularization progressed, compared with the normal level of 20.76 ± 0.41 mmol.
Administration of ursolic acid significantly reduced the serum nitrite level to 18.4 ± 0.797 mmol at 24 hours and to 23.5 ± 0.399 mmol on the ninth day after angiogenesis induction. The effect of ursolic acid on serum nitrite levels is shown in Table 2 .
Effect of Ursolic Acid on Serum TIMP-1 and IL-2 Levels During Angiogenesis
The serum TIMP-1 levels showed significant enhancement in ursolic acid-treated animals after 24 hours and on the ninth day compared with the levels in controls (Table 3) . After 24 hours, the TIMP-1 level of control animals was only 352.52 ± 5.23 pg/mL, but it increased significantly to 951.07 ± 3.69 pg/mL in the ursolic acid-treated group. On the ninth day, the ursolic acid-treated animals showed significant enhancement in TIMP-1 levels to 1074.96 ± 29.57 pg/mL compared with the untreated tumor-bearing controls (362.97 ± 5.23 pg/mL). The level of IL-2 was found to be lowered in angiogenesisinduced animals after 24 hours of tumor induction (16.03 ± 0.42 pg/mL) when compared with the normal value (23.43 ± 2.45 pg/mL), and it remained at the lowered level throughout the period of study (Table 3 ). When angiogenesis-induced animals were treated with ursolic acid, the IL-2 level increased to 26.61 ± 0.21 pg/mL and reached a value of 54.73 ± 0.32 pg/mL on the ninth day. The serum IL-2 level of vehicle-only-treated control animals was only 18.21 ± 0.34 pg/mL.
Effect of Ursolic Acid on Proinflammatory Cytokine Levels in Serum During Angiogenesis
Alteration in serum proinflammatory cytokine levels was observed in C57BL/6 mice in response to angiogenesis (Table 4 ). In control animals, the TNF-a level was drastically elevated to 166.22 ± 1.05 pg/mL at 24 hours of angiogenesis induction and to 571.8 ± 7.1 pg/mL on the ninth day when compared with the normal level (20 ± 3.2 pg/mL). Administration of ursolic acid was found to effectively lower the elevated TNF-a level to 159.07 ± 0.91 pg/mL after 24 hours and to 142.3 ± 1.15 pg/mL on the ninth day of angiogenesis induction.
The normal level of IL-1b is 16.13 ± 1.72 pg/mL. In angiogenesis-induced animals, it was elevated to 31.44 ± 1.04 pg/mL after 24 hours and to 32.25 ± 0.46 pg/mL on the ninth day. Administration of ursolic acid significantly lowered this level to 30.67 ± 0.46 pg/mL and 16.68 ± 1.57 pg/ mL, respectively, at the 24th hour and on the ninth day of tumor induction (Table 4 ).
Serum IL-6 level was slightly increased at 24 hours in controls (41.22 ± 2.44 pg/mL) from the normal level of 35.9 ± 3.6 pg/mL. On the ninth day, it was drastically elevated to 326.3 ± 3.99 pg/mL in control animals, whereas it was significantly reduced to 71.27 ± 3.56 pg/mL in ursolic acid-treated animals ( Table 4 ).
Cytotoxic Activity of Ursolic Acid Toward HUVECs in Culture by MTT Assay
Nontoxic concentrations of ursolic acid to HUVECs for the in vitro studies were determined by MTT assay. Ursolic acid was found to be 39% and 79.1% cytotoxic to HUVECs at a concentration of 100 mM and 75 mM, respectively, and nontoxic at concentrations of 50, 25, and 10 mM (Figure 3 ). Blood was collected from the angiogenesis-induced animals at the indicated time points after tumor challenge. Serum was separated and VEGF level was estimated using a highly specific ELISA Kit for VEGF purchased from R & D system, USA. Serum was also used for NO estimation by Griess reaction and is expressed as amount of nitrite. Values are given as mean ± standard deviation. b P < .001 compared with control. Blood was collected from the angiogenesis-induced animals at the indicated time points after tumor challenge. Serum was separated by centrifugation, and the cytokine level was estimated by ELISA method. All the values are mean ± standard deviation. b P < .001 compared with control.
These nontoxic concentrations of ursolic acid (50, 25, and 10 mM) were used for in vitro studies.
Effect of Ursolic Acid on the Microvessel Outgrowth From the Rat Aortic Ring (Rat Aortic Ring Assay)
As shown in Figure 4A , conditioned medium from untreated B16F10 melanoma cells stimulated the microvessel outgrowth from rat thoracic aorta. The presence of ursolic acid inhibited the microvessel sprouting from rat thoracic aorta induced by B16F10 melanoma-conditioned medium in a dose-dependent manner (Figures 4B, 4C , and 4D).
Effect of Ursolic Acid on Endothelial Cell Proliferation
Rate of proliferation was determined by 3 H-thymidine incorporation by the DNA of HUVECs. Thymidine incorporation is proportional to the potential of the cells to synthesize DNA. Proliferation was expressed as radioactive count per minute (cpm). HUVECs showed a very high rate of proliferation (4790 ± 80 cpm) when stimulated with VEGF. Administration of ursolic acid at a concentration of 50 mM significantly inhibited (45.5%, 2609 ± 62 cpm) VEGF-induced proliferation of HUVECs. Considerable inhibition of proliferation was also observed when ursolic acid was administered at concentrations of 25 mM (33.9%, 3162 ± 105 cpm) and 10 mM (12.4%, 4197 ± 60 cpm; Table 5 ).
Effect of Ursolic Acid on B16F-10 Melanoma Cell Proliferation
Rate of proliferation of B16F-10 cells was also determined by 3 H-thymidine incorporation assay. Untreated B16F-10 cells showed a very high rate of proliferation (5172 ± 167 cpm). Administration of ursolic acid at a concentration of 50 mM significantly inhibited (53.4%, 2411 ± 92 cpm) the proliferation of B16F-10 cells. Considerable inhibition of proliferation was also observed when ursolic acid was administered at concentrations of 25 mM (35.9%, 3317 ± 85 cpm) and 10 mM (9.6%, 4679 ± 130 cpm; Table 6 ).
Effect of Ursolic Acid on Endothelial Cell Migration/Motility
Effect of ursolic acid on the motility of HUVECs is shown in Figure 5 . HUVECs migrated into the clear area when stimulated with VEGF ( Figure 5B ). Ursolic acid significantly inhibited the VEGF-induced migration of endothelial cells in a dose-dependent manner (Figures 5C, 5D, and 5E) . At a concentration of 50 mM, ursolic acid significantly inhibited the migration of HUVECs by 89.4% ( Figure 5C ), whereas at 25 mM and 10 mM, the inhibition of migration was found to be 61.2% ( Figure 5D ) and 49% ( Figure 5E ), respectively.
Effect of Ursolic Acid on Endothelial Cell Invasion
HUVECs showed a highly invasive property through the collagen matrix when stimulated with VEGF and fibroblast growth factor ( Figure 6A ). Large numbers of cells were found on the lower surface of the polycarbonate membrane, but administration of ursolic acid produced significant inhibition in the invasion of the collagen matrix by HUVECs in a dose-dependent manner. At a concentration of 50 mM, ursolic acid significantly inhibited the invasion of HUVECs by 91.3% ( Figure 6B ), whereas at 25mM and 10 mM, the inhibition of invasion was found to be 73.9% ( Figure 6C ) and 41.1% ( Figure 6D ), respectively.
Effect of Ursolic Acid on MMPs by Gelatin Zymography
The major forms of proteases detected by gelatin zymography are type IV collagenases, MMP-2 and MMP-9 (Figure 7 ).
Because these proteases secreted by the cells into the conditioned medium are mainly proenzymes (latent form requiring activation), an activation step (trypsin activation) is necessary to get the MMPs activated. Conditioned medium after trypsin activation showed digested clear areas at 92 kD and 72 kD, which were identical to MMP-9 and MMP-2 activity. Gels loaded with conditioned medium without trypsin activation did not show clear degradative areas, indicating the inactive form of the enzyme. Trypsinactivated conditioned-medium-loaded gels when incubated with 10 mM EDTA (EDTA inhibits the proteolytic activity by chelating Ca+) did not show clear degradative areas, which indicates that the enzyme responsible for degradation is metalloproteinase. Conditioned medium from HUVECs pretreated with ursolic acid (50, 25, and 10 mM) after trypsin activation did not show any digested clear areas, indicating that ursolic acid could inhibit cellular release of MMPs from HUVECs.
Effect of Ursolic Acid on the Expression of iNOS and VEGF Genes in B16F-10 Melanoma Cells
The agarose gel electrophoresis shows (Figure 8 ) that the expression of the iNOS gene was downregulated in B16F-10 melanoma cells treated with a nontoxic concentration of ursolic acid (50 mM) when compared with the untreated control cells. The VEGF gene also had diminished expression in ursolic acid-treated (50 mM) B16F-10 melanoma cells when compared with the untreated cells.
Discussion
Because of nutritional and oxygen limitations, avascular tumors in vivo are restricted in size and activity. In the case of malignant tumors, hypoxia and nutrient limitation stimulate production of proangiogenic factors, actively recruiting existing vasculature and establishing a network of blood vessels throughout the tumor. 35, 36 Different factors produced by tumor cells and surrounding stromal cells play important roles in regulating tumor angiogenesis by activating or blocking different pathways. 36 To use the antiangiogenesis approach successfully as an anticancer therapy, it is essential to identify the agents that can stimulate antiangiogenic factors as well as demote proangiogenic factors. In the present study, we provide the data that outline the antiangiogenic activity of ursolic acid, a naturally occurring triterpene. Tumor vessel count has been shown to be directly correlated with the survival of tumor cells, 37 and administration of ursolic acid significantly inhibited tumorspecific new blood vessel formation in C57BL/6 mice when angiogenesis was induced with them with B16F-10 melanoma cells. The process of angiogenesis consists of several steps, which include the stimulation of endothelial cells by growth factors such as VEGF, release of proteolytic enzymes like MMPs, the subsequent degradation of the extracellular matrix (ECM) followed by invasion through ECM, migration and proliferation of endothelial cells, and finally, the formation of new capillary tubes. 38 The most well-characterized angiogenic factor is VEGF. 39 VEGF controls several fundamental aspects of endothelial cell function. In our study, the induction of B16F-10 melanoma cells intradermally to mice caused a sudden elevation in the level of VEGF within 24 hours. Administration of ursolic acid could reduce these increased serum VEGF levels showing the antiangiogenic activity. This may be because of the downregulatory action of ursolic acid on VEGF gene expression because there was only diminished expression of VEGF when B16F-10 melanoma cells were treated with ursolic acid.
Cancer cells can also stimulate angiogenesis directly by the secretion of some of the proinflammatory cytokines such as TNF and IL-1. 40 TNF has proinflammatory activity by upregulating proteins such as prostaglandin E2, MMP-1, IL-6, cell adhesion molecule (ICAM-1), and E-selectin and induces secretion of some chemokines such as IL-8. 41, 42 It may function as a key cytokine in the tumor angiogenic switch. 43 Pleiotropic cytokines such as IL-1b, IL-6, and TNF-a can act as autocrine growth factors for tumor cells. In the present study, the serum levels of proinflammatory cytokines such as TNF-a, IL-1b, and IL-6 were found to be downregulated in angiogenesis-induced mice. We have already reported that ursolic acid induced suppression of proinflammatory cytokine genes and transcription factors NF-kB, AP-1, and CREB-1 in B16F-10 melanoma cells. 25 The present study demonstrated that ursolic acid could significantly inhibit the proliferation of B16F-10 melanoma cells, which supports our previous reports of ursolic acidinduced downregulation of survival signals and induction of apoptosis. 25 TNF-a might be directly involved in iNOS activation and act as an additional signal for synergistic induction of NO formation. Several studies have pointed to the critical role of NO in VEGF-induced vascular permeability as well as inangiogenesis. 9, 44 The results of the present study are well correlated with these findings. Intradermal introduction of highly metastatic B16F-10 melanoma cells resulted in drastic elevation of serum NO level of untreated angiogenesis-induced animals, which may be the reason for increased tumor-directed capillary formation in them. Administration of ursolic acid significantly reduced the elevated serum NO levels after tumor challenge, which in turn resulted in decreased tumor-directed capillary formation. The downregulated expression of iNOS gene in ursolic acid-treated B16F-10 melanoma cells also supports the above observation. Moreover, the rat aortic ring assay also showed inhibition in the sprouting of new vessels from the preexisting endothelial cells, which strongly supports the efficacy of ursolic acid in suppressing neovascularization.
Studies on the effect of ursolic acid on the serum levels of IL-2 showed that administration of ursolic acid significantly enhanced the serum IL-2 level in angiogenesis-induced animals compared with untreated control animals. IL-2 was the first cytokine used clinically for treating cancer. 45 It has been reported that IL-2 augments innate immunity by stimulating natural killer cells and also promotes proliferation and differentiation of helper T-cells, cytotoxic T-cells, and B-cells. 46 Angiogenesis occurs through a series of interrelated steps, including endothelial cell proliferation, motility, and invasion of endothelial cells through the ECM toward the angiogenic stimuli. Cardenas et al 29 showed that ursolic acid could inhibit the different steps of the angiogenesis process using BAE cells. The 3 H thymidine incorporation assay is a direct measurement of the proliferation rate of cells. In our study, nontoxic concentrations of ursolic acid significantly reduced the proliferation rate of HUVECs, showing its direct action on endothelial cells.
Vascular remodeling of the ECM is an essential part of angiogenesis. 47 Remodeling is the reorganization of the ECM, which is a complex and dynamic network assembled outside the cell, using specific secreted glycoproteins and proteoglycans. MMPs and tissue inhibitors of metalloproteinases play a major regulatory role in matrix reorganization. 48 The endothelial cells must penetrate this ECM to make a new vessel. To achieve this feat, endothelial cells use an endogenous proteolytic pathway, 47 and the family of zincdependent enzymes known as MMPs has received substantial attention in this regard. MMPs are generally secreted as proforms that are activated by proteolytic cleavage. In MMP-9-deficient mice, reduced angiogenesis has been reported, highlighting the role of this protease for angiogenesis. 49 Gelatin zymographic analysis clearly revealed that treatment of ursolic acid inhibited the MMP-2 and MMP-9 protein expressions in HUVECs, supporting the above observation. These proteinases expose new cryptic epitopes in ECM proteins or change their structure, which induces endothelial cell migration. 50 In this study, the wound healing assay clearly demonstrated the effect of ursolic acid in inhibiting the endothelial cell migration using HUVECs. It has been reported that MMPs form minute holes in the sheath-like basement membrane surrounding blood vessels to allow endothelial cells to invade. 51 Proangiogenic factors stimulate endothelial cells to migrate and invade the ECM toward the chemotactic angiogenic stimuli. The present study revealed that the HUVECs treated with ursolic acid have less invasive potential in a gelatin-coated membrane, which also correlates with the down regulated expressions of MMP-2 and MMP-9 proteins in gelatin zymography.
TIMP directly suppresses the MMP activity, thereby, inhibiting ECM remodeling. It also inhibits angiogenic factor-induced endothelial cell proliferation both in vitro and in vivo independent of MMP inhibition. 5 In the present study, the level of serum TIMP-1 was significantly enhanced in ursolic acid-treated animals both at the 24th hour and on the ninth day of angiogenesis induction as compared with the untreated controls.
The present study clearly demonstrated that ursolic acid inhibits tumor-directed capillary formation and endothelial cell proliferation, migration, and invasion by reducing the production of VEGF, MMP-2, MMP-9, and NO. From all the observations in this study, we conclude that ursolic acid is a potent antiangiogenic agent.
